Loading
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (1 ops.)
Latest filing published 20 Nov 2024 for Syros Pharmaceuticals, Inc.. Read the official filing
Insider track record
Disclosed buys
0
Disclosed sells
1
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
No signal scores available.
Kristin Stephens: trading record in brief
Kristin Stephens, listed as senior executive, appears in our data through filings on Syros Pharmaceuticals, Inc. shares, published by SEC (Form 4). In total, 6 filings cover trades dated from 1 April 2022 to 18 November 2024.
Every open-market trade on record is a sale: 1 sale. The totals do not cover 1 filing with an undisclosed amount. Other entries cover 1 share grant and 4 option exercises. So far in 2024, the count stands at no purchases and 1 sale.
On 20 November 2024 came the latest disclosure, an open-market sale in Syros Pharmaceuticals, Inc. The median gap between a trade and its publication by SEC (Form 4) is 3 days. US insiders must file a Form 4 within two business days of a trade. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Companies and markets linked to Kristin Stephens
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations6 total
36,133 shares@ €0.208934.6% of flowCommon StockSEC:0000950170-24-129384:0
17,000 sharesCommon StockSEC:0000950170-24-120863:0
2,000 sharesCommon StockSEC:0000950170-24-040320:0
17,000 sharesCommon StockSEC:0001209191-23-054168:0
2,000 sharesCommon StockSEC:0001209191-23-022971:0
14,115 shares@ €1.0115100.0% of flowCommon StockSEC:0001209191-22-022508:0
6 of 6 declarations
